Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrop⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$31.41
Price-2.73%
-$0.88
$3.019b
Mid
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$315.687m
-
1y CAGR-
3y CAGR-
5y CAGR-$2.98
-
1y CAGR-
3y CAGR-
5y CAGR$233.293m
$340.045m
Assets$106.752m
Liabilities$61.529m
Debt18.1%
-0.2x
Debt to EBITDA-$258.123m
-
1y CAGR-
3y CAGR-
5y CAGR